HRP20202024T1 - Cd3-vežuća domena - Google Patents
Cd3-vežuća domena Download PDFInfo
- Publication number
- HRP20202024T1 HRP20202024T1 HRP20202024TT HRP20202024T HRP20202024T1 HR P20202024 T1 HRP20202024 T1 HR P20202024T1 HR P20202024T T HRP20202024T T HR P20202024TT HR P20202024 T HRP20202024 T HR P20202024T HR P20202024 T1 HRP20202024 T1 HR P20202024T1
- Authority
- HR
- Croatia
- Prior art keywords
- binding protein
- antigen
- antigen binding
- domain
- seq
- Prior art date
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims 22
- 108091000831 antigen binding proteins Proteins 0.000 claims 22
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 108091008324 binding proteins Proteins 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 102000056982 human CD33 Human genes 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Gyroscopes (AREA)
- Optical Communication System (AREA)
Claims (15)
1. Antigenski vežući protein, naznačen time što sadrži najmanje jedno CD3-vežuće mjesto, gdje CD3-vežuće mjesto sadrži:
(a) domenu varijabilnog teškog lanca (VH) kao što je opisano u SEQ ID NO:8 i domenu varijabilnog lakog lanca (VL) kao što je opisano u SEQ ID NO:3; ili
(b) domenu varijabilnog teškog lanca (VH) kao što je opisano u SEQ ID NO:9 i domenu varijabilnog lakog lanca (VL) kao što je opisano u SEQ ID NO:4; ili
(c) domenu varijabilnog teškog lanca (VH) čiji je slijed najmanje 95% istovjetan u usporedbi s VH kao što je opisano u SEQ ID NO:8, gdje je aminokiselinski ostatak na položaju 111 Y ili H, i domenu varijabilnog lakog lanca (VL) čiji je slijed najmanje 95% istovjetan u usporedbi s VL kao što je opisano u SEQ ID NO:3, gdje je aminokiselinski ostatak na položaju 49 G ili A; ili
(d) domenu varijabilnog teškog lanca (VH) koja sadrži 1 do 5 konzerviranih aminokiselinskih zamjena u usporedbi s VH kao što je opisano u SEQ ID NO:8, gdje je aminokiselinski ostatak na položaju 111 Y ili H, i domenu varijabilnog lakog lanca (VL) koja sadrži 1 do 5 konzerviranih aminokiselinskih zamjena u usporedbi s VL kao što je opisano u SEQ ID NO:3, gdje je aminokiselinski ostatak na položaju 49 G ili A; i
antigenski vežući protein iz (a), (b), (c) ili (d) nije bispecifični vežući protein koji se specifično veže na ljudski CD33 i ljudski CD3, gdje CD3-vežuće mjesto sadrži domena varijabilnog lakog lanca protiv CD3 koju se bira iz skupine koju čine SEQ ID NO:1-3 i domena varijabilnog teškog lanca protiv CD3 koju se bira iz skupine koju čine SEQ ID NO:6-8.
2. Antigenski vežući protein u skladu s patentnim zahtjevom 1, naznačen time što antigenski vežući protein nije bispecifično tandemno dijatijelo kojom se veže na CD33 i CD3.
3. Antigenski vežući protein u skladu s patentnim zahtjevom 1 ili 2, naznačen time što protein sadrži najmanje jednu dodatnu funkcionalnu domenu.
4. Antigenski vežući protein u skladu s patentnim zahtjevom 3, naznačen time što je najmanje jedna dodatna funkcionalna domena dodatno antigenski vežuće mjesto.
5. Antigenski vežući protein u skladu s patentnim zahtjevom 4, naznačen time što je dodatno antigenski vežuće mjesto specifično za tumorsku stanicu.
6. Antigenski vežući protein u skladu s patentnim zahtjevom 5, naznačen time što dodatno antigenski vežuće mjesto nije specifično za CD33.
7. Antigenski vežući protein u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je antigenski vežući protein polivalentan.
8. Antigenski vežući protein u skladu s patentnim zahtjevom 7, naznačen time što je antigenski vežući protein multispecifično.
9. Antigenski vežući protein u skladu s patentnim zahtjevom 8, naznačen time što je antigenski vežući protein polimerni.
10. Antigenski vežući protein u skladu s patentnim zahtjevom 9, naznačen time što je antigenski vežući protein dimerni, te sadrži prvi polipeptid i drugi polipeptid, gdje svaki polipeptid ima najmanje četiri domene varijabilnog lanca spojene jedna za drugom, gdje antigenski vežući protein sadrži najmanje jedno CD3-vežuće mjesto u skladu s patentnim zahtjevom 1 i najmanje jedno dodatno antigenski vežuće mjesto specifično za drugi antigen.
11. Antigenski vežući protein u skladu s patentnim zahtjevom 10, naznačen time što svaki polipeptid ima najmanje četiri varijabilne domene, međusobno fuzionirane peptidnim spojnicama L1, L2 i L3 sljedećim redoslijedom:
(i) VL (CD3)-L1-VH(2. antigen)-L2-VL(2. antigen)-L3-VH(CD3);
(ii) VH (CD3)-L1-VL(2. antigen)-L2-VH(2. antigen)-L3-VL(CD3);
(iii) VL(2. antigen)-L1-VH(CD3)-L2-VL(CD3)-L3-VH(2. antigen); ili
(iv) VH(2. antigen)-L1-VL(CD3)-L2-VH(CD3)-L3-VL(2. antigen).
12. Antigenski vežući protein u skladu s patentnim zahtjevom 10, naznačen time što se spojnice L1, L2 i L3 sastoje od otprilike 12 ili manje aminokiselinskih ostataka.
13. Polinukleotid, naznačen time što kodira antigenski vežući protein u skladu s bilo kojim od patentnih zahtjeva 1 do 12.
14. Farmaceutski pripravak, naznačen time što sadrži (i) antigenski vežući protein u skladu s bilo kojim od patentnih zahtjeva 1 do 12, polinukleotid u skladu s patentnim zahtjevom 13 ili vektor koji sadrži polinukleotid u skladu s patentnim zahtjevom 13 i (ii) farmaceutski prihvatljivi nosač.
15. Antigenski vežući protein u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što je namijenjen upotrebi kao medikament.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2014/002177 WO2015018527A1 (en) | 2013-08-07 | 2014-08-07 | ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII |
| EP15154772.6A EP2982693A1 (en) | 2014-08-07 | 2015-02-11 | CD3 binding domain |
| EP15756850.2A EP3177646B1 (en) | 2014-08-07 | 2015-08-05 | Cd3 binding domain |
| PCT/EP2015/068070 WO2016020444A1 (en) | 2014-08-07 | 2015-08-05 | Cd3 binding domain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20202024T1 true HRP20202024T1 (hr) | 2021-02-19 |
Family
ID=52468915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20202024TT HRP20202024T1 (hr) | 2014-08-07 | 2020-12-17 | Cd3-vežuća domena |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10066015B2 (hr) |
| EP (2) | EP2982693A1 (hr) |
| JP (1) | JP6669722B2 (hr) |
| CN (1) | CN107001468B (hr) |
| AU (1) | AU2015299039B2 (hr) |
| BR (1) | BR112017002422B1 (hr) |
| CA (1) | CA2957462C (hr) |
| DK (1) | DK3177646T3 (hr) |
| HR (1) | HRP20202024T1 (hr) |
| HU (1) | HUE051919T2 (hr) |
| LT (1) | LT3177646T (hr) |
| RU (1) | RU2742691C2 (hr) |
| SI (1) | SI3177646T1 (hr) |
| WO (1) | WO2016020444A1 (hr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2929256C (en) | 2013-11-04 | 2022-04-26 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| IL307276A (en) | 2015-08-28 | 2023-11-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| US11702477B2 (en) | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| CN108290954B (zh) | 2015-12-09 | 2022-07-26 | 豪夫迈·罗氏有限公司 | Ii型抗cd20抗体用于降低抗药物抗体形成 |
| DK3411398T3 (da) | 2016-02-05 | 2024-06-24 | Orionis Biosciences BV | Målrettede terapeutiske midler og anvendelse heraf |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| US10906985B2 (en) | 2017-02-06 | 2021-02-02 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| JP7556687B2 (ja) | 2017-02-24 | 2024-09-26 | 中外製薬株式会社 | 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法 |
| EP3366704A1 (en) | 2017-02-28 | 2018-08-29 | Affimed GmbH | Antibodies specific for mmp1/hla-a2 complex |
| BR112019020940A2 (pt) | 2017-04-11 | 2020-05-05 | Inhibrx Inc | construções polipeptídicas multipecíficas que têm ligação a cd3 restrita e métodos de usar as mesmas |
| EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| KR20200014304A (ko) | 2017-06-02 | 2020-02-10 | 에프. 호프만-라 로슈 아게 | 암의 치료를 위한 제ii형 항-cd20 항체 및 항-cd20/항-cd3 이중특이적 항체 |
| WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| AU2018280681A1 (en) * | 2017-06-05 | 2019-12-05 | Numab Therapeutics AG | Novel anti-CD3 antibodies |
| EP3668898B1 (en) | 2017-08-14 | 2023-07-05 | MorphoSys AG | Humanized antibodies for cd3 |
| KR101973060B1 (ko) * | 2017-10-20 | 2019-04-26 | 주식회사 녹십자 | 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| EP3502140A1 (en) * | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
| EP3753956A4 (en) * | 2018-02-14 | 2021-12-22 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN BINDING MOLECULE AND COMBINATION |
| EP3765520A1 (en) * | 2018-03-14 | 2021-01-20 | NovImmune SA | Anti-cd3 epsilon antibodies and methods of use thereof |
| US11603405B2 (en) * | 2018-05-24 | 2023-03-14 | Janssen Biotech, Inc. | Anti-CD3 antibodies and uses thereof |
| SG11202101608XA (en) * | 2018-08-23 | 2021-03-30 | Regeneron Pharma | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
| AU2019439345B2 (en) * | 2019-03-29 | 2024-08-08 | Green Cross Corporation | Fusion protein comprising anti-mesothelin antibody, anti-CD3 antibody or anti-EGFR antibody, bispecific or trispecific antibody comprising same, and uses thereof |
| TW202140561A (zh) * | 2020-02-14 | 2021-11-01 | 日商協和麒麟股份有限公司 | 與cd3結合之雙特異性抗體 |
| CA3217803A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
| JP2024517535A (ja) | 2021-04-30 | 2024-04-23 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体と抗ｃｄ７９ｂ抗体薬物コンジュゲートを用いた併用治療の投与 |
| JP2024523033A (ja) | 2021-06-17 | 2024-06-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の三重特異的結合分子 |
| KR20240130125A (ko) | 2021-12-31 | 2024-08-28 | 카이노 바이오테크놀로지 컴퍼니 리미티드 | 항-gprc5d 항체 및 그의 응용 |
| CN116375868A (zh) * | 2021-12-31 | 2023-07-04 | 康源博创生物科技(北京)有限公司 | 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用 |
| US20230414750A1 (en) | 2022-03-23 | 2023-12-28 | Hoffmann-La Roche Inc. | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
| AU2023251832A1 (en) | 2022-04-13 | 2024-10-17 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| WO2024152963A1 (zh) * | 2023-01-18 | 2024-07-25 | 贝达药业股份有限公司 | 抗cd3的人源化抗体及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1297090B1 (it) * | 1997-12-01 | 1999-08-03 | Barbara Ensoli | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
| EP1165791B1 (en) * | 1999-03-09 | 2007-10-31 | ZymoGenetics, Inc. | Human cytokine as ligand of the zalpha receptor and uses thereof |
| DE60124912T2 (de) | 2001-09-14 | 2007-06-14 | Affimed Therapeutics Ag | Multimerische, einzelkettige, Tandem-Fv-Antikörper |
| DE602005022830D1 (de) | 2004-02-16 | 2010-09-23 | Micromet Ag | Weniger immunogene bindungsmoleküle |
| RU2506275C2 (ru) * | 2007-11-01 | 2014-02-10 | Астеллас Фарма Инк. | Иммуносупрессорные полипептиды и нуклеиновые кислоты |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| AU2012233313C1 (en) * | 2011-03-30 | 2017-08-03 | Chugai Seiyaku Kabushiki Kaisha | Method for altering plasma retention and immunogenicity of antigen-binding molecule |
| CA2836857C (en) * | 2011-05-21 | 2019-12-03 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| JP2016510319A (ja) * | 2012-12-28 | 2016-04-07 | アッヴィ・インコーポレイテッド | 多価結合タンパク質組成物 |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US20140242077A1 (en) | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| WO2015018527A1 (en) * | 2013-08-07 | 2015-02-12 | Affimed Therapeutics Ag | ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII |
| US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
-
2015
- 2015-02-11 EP EP15154772.6A patent/EP2982693A1/en not_active Withdrawn
- 2015-08-05 LT LTEP15756850.2T patent/LT3177646T/lt unknown
- 2015-08-05 DK DK15756850.2T patent/DK3177646T3/da active
- 2015-08-05 CN CN201580054757.1A patent/CN107001468B/zh active Active
- 2015-08-05 CA CA2957462A patent/CA2957462C/en active Active
- 2015-08-05 SI SI201531457T patent/SI3177646T1/sl unknown
- 2015-08-05 AU AU2015299039A patent/AU2015299039B2/en active Active
- 2015-08-05 EP EP15756850.2A patent/EP3177646B1/en active Active
- 2015-08-05 JP JP2017506890A patent/JP6669722B2/ja active Active
- 2015-08-05 RU RU2017105120A patent/RU2742691C2/ru active
- 2015-08-05 WO PCT/EP2015/068070 patent/WO2016020444A1/en active Application Filing
- 2015-08-05 BR BR112017002422-5A patent/BR112017002422B1/pt active IP Right Grant
- 2015-08-05 HU HUE15756850A patent/HUE051919T2/hu unknown
- 2015-08-06 US US14/820,462 patent/US10066015B2/en active Active
-
2020
- 2020-12-17 HR HRP20202024TT patent/HRP20202024T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3177646B1 (en) | 2020-10-07 |
| CN107001468A (zh) | 2017-08-01 |
| RU2017105120A3 (hr) | 2019-02-20 |
| DK3177646T3 (da) | 2020-12-07 |
| AU2015299039A1 (en) | 2017-03-02 |
| BR112017002422A2 (pt) | 2017-11-28 |
| JP2017529067A (ja) | 2017-10-05 |
| AU2015299039B2 (en) | 2021-01-21 |
| HUE051919T2 (hu) | 2021-04-28 |
| RU2742691C2 (ru) | 2021-02-09 |
| EP3177646A1 (en) | 2017-06-14 |
| CA2957462A1 (en) | 2016-02-11 |
| CA2957462C (en) | 2023-10-17 |
| JP6669722B2 (ja) | 2020-03-18 |
| RU2017105120A (ru) | 2018-09-10 |
| SI3177646T1 (sl) | 2021-04-30 |
| US10066015B2 (en) | 2018-09-04 |
| LT3177646T (lt) | 2021-01-11 |
| BR112017002422B1 (pt) | 2024-02-20 |
| EP2982693A1 (en) | 2016-02-10 |
| CN107001468B (zh) | 2021-04-09 |
| WO2016020444A1 (en) | 2016-02-11 |
| US20160039934A1 (en) | 2016-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20202024T1 (hr) | Cd3-vežuća domena | |
| JP2017529067A5 (hr) | ||
| HRP20240767T1 (hr) | Cd3 vezujuća antitijela | |
| HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| HRP20201156T1 (hr) | Zajednički laki lanci i postupci primjene | |
| HRP20191704T1 (hr) | Multispecifična protutijela | |
| HRP20191775T1 (hr) | Multispecifične konstrukcije antitijela | |
| CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| HRP20191839T1 (hr) | Car ekspresijski vektor i t stanice koje eksprimiraju car | |
| JP2016536322A5 (hr) | ||
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| HRP20240576T1 (hr) | Cd19 specifični kimerni antigenski receptor i njegova upotreba | |
| HRP20230060T1 (hr) | Antitijela protiv ox40 i njihova primjena | |
| RU2019100481A (ru) | Биспецифические антитела-ингибиторы контрольных точек | |
| JP2016196468A5 (hr) | ||
| PE20181066A1 (es) | Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| HRP20220891T1 (hr) | Protutijela, primjene i postupci | |
| HRP20211794T1 (hr) | Humana antitijela za pd-1 | |
| RU2017102312A (ru) | Конструкции мультиспецифичных антител | |
| AR101829A1 (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 | |
| PE20220495A1 (es) | Receptores antigenicos quimericos y agentes de union dirigidos a dll3 | |
| NZ715896A (en) | Humanized or chimeric cd3 antibodies |